|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
The Procters and Altrias are the L.T. and Ray Lewis of the stock market: They know how to score for you.
The joint implant firm's heavily touted minimally invasive surgery technique draws critics.
But the company's shares slip as Zimmer trims second-half sales forecasts.
But HCA continues to be hit by uninsured patient costs. Plus, gains at Exactech.
But expectations are already sky-high for the big maker of orthopedic implants.
Cost-cutting efforts in the cash-strapped hospital sector could pinch orthopedic implant profits.
Not able to meet fourth-quarter expectations, the company boosts its dividend and buys back stock.
The chatter is tiresome, but that doesn't mean prices are too high. Also, charts of Beazer and more.
Companies like Zimmer, Biomet and Stryker could see margins narrow as orthopedic prices come under pressure.
This atmosphere produces the largest percentage of stocks with growth in earnings.
Jim Cramer presents the second half of his top 10 picks of what can be bought after a three-day rally.
Critics say improvements in the implant maker's newer hip and knee joints are mostly for show.
That's the takeaway from the Schlumberger call, where it became clear that it's still too early to sell the drillers.
Orthopedic device makers such as Zimmer and Smith & Nephew could be vulnerable, some say.
Hospitals claim the feds have let implant makers such as DePuy, Biomet and Zimmer ratchet up prices. Now change is in the air.
The government wants to take a look at some lucrative consulting arrangements.
The Chartman's taking his computer and charts on vacation, but should you? Also charts on Fannie Mae, Yahoo! and more.
A Bush win should give these stocks a shot in the arm, but the longer view isn't optimistic.
A big nest egg or alternative income sources is key to success. Plus, charts of PeopleSoft, Kinross Gold and more.
The company is making money hand-over-fist and offers some relief from presidential-race worries.
A big change to a position helps Cramer escape some of the ebb and flow as earnings wear on.
With earnings season on the horizon, it's time to get a game plan in place.
Cramer decides what to do about the late-week rotation into tech and looks at his exposure for the coming week.
At the end of a weak week, Cramer looks at his portfolio and what might work next.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.